Perioperative Dexmedetomidine or Lidocaine Infusion for the Prevention of Chronic Postoperative and Neuropathic Pain After Gynecological Surgery: A Randomized, Placebo-Controlled, Double-Blind Study

被引:11
|
作者
Rekatsina, Martina [1 ]
Theodosopoulou, Polyxeni [2 ]
Staikou, Chryssoula [2 ]
机构
[1] Mid & South Essex NHS Fdn Trust, Basildon Univ Hosp, London, England
[2] Natl & Kapodistrian Univ Athens, Aretaie Hosp, Med Sch, Athens, Greece
关键词
Dexmedetomidine; Lidocaine; Chronic postoperative pain; Neuropathic pain; Long-term follow-up; PERSISTENT POSTSURGICAL PAIN; DIAGNOSTIC QUESTIONNAIRE; SYSTEMIC LIDOCAINE; LOCAL-ANESTHETICS; RISK-FACTORS; FOLLOW-UP; HYSTERECTOMY; CONSUMPTION; SYMPTOMS; VERSION;
D O I
10.1007/s40122-022-00361-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction The transition of acute to chronic postoperative pain (CPP) remains a significant burden to the rehabilitation of patients. The research for adjuvants to prevent CPP continues; among others, dexmedetomidine and lidocaine seem promising agents. Methods This is a long-term follow-up of a randomized, placebo-controlled, double-blind study on women who underwent open abdominal gynecological surgery and received dexmedetomidine or lidocaine or placebo infusion perioperatively (n = 81). The effect of these adjuvants on the development of CPP and neuropathic pain was assessed during a 12-month follow-up. Eighty-one (81) women ASA I-II, aged between 30 and 70 years, were randomly assigned to receive either dexmedetomidine (DEX group) or lidocaine (LIDO group) or placebo (CONTROL group) perioperatively. Before anesthesia induction, all patients received a loading intravenous dose of either 0.6 mu g/kg dexmedetomidine or 1.5 mg/kg lidocaine or placebo, followed by 0.6 mu g/kg/h dexmedetomidine or 1.5 mg/kg/h lidocaine or placebo until last suture. Patients were followed up to obtain the long-term outcomes at 3, 6, and 12 months. At these time-points, pain intensity was assessed with the Numerical Rating Scale, (NRS: 0-10) and the development of neuropathic elements with the Douleur Neuropathique 4 (DN4) score. Prognostic parameters that could affect chronic pain and its components were also identified. Results Data from 74 women were analyzed. Dexmedetomidine significantly reduced NRS scores comparing to placebo at 3 months (p = 0.018), while at 6 months, lidocaine was found superior to placebo (p = 0.02), but not to dexmedetomidine, in preventing neuropathic pain (DN4 < 4). Regarding secondary endpoints, higher NRS cough scores at 48 h were associated with statistically significant NRS and DN4 scores at 3, 6, and 12 months (p < 0.02). At 6 months, a statistically significant correlation was also found between higher NRS values and older age (p = 0.020). Conclusions Dexmedetomidine was superior to placebo regarding the duration and severity of CPP, while lidocaine exhibited a protective effect against neuropathic elements of CPP.
引用
收藏
页码:529 / 543
页数:15
相关论文
共 50 条
  • [21] Effect of intravenous lidocaine on chronic postoperative pain in patients undergoing breast cancer surgery: a prospective, double-blind, randomized, placebo-controlled clinical trial
    Xia, Ming
    Wei, Qingfeng
    Zhang, Qin
    Jiang, Hong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (14)
  • [22] Long-term pain outcomes after serial lidocaine infusion in participants with recent onset of peripheral neuropathic pain: A pilot double-blind, randomized, placebo-controlled trial
    Wangnamthip, Suratsawadee
    Euasobhon, Pramote
    Thiangtham, Kasamabhorn
    Jirachaipitak, Sukunya
    Rushatamukayanunt, Pranee
    Jensen, Mark P.
    MEDICINE, 2024, 103 (21) : E38253
  • [23] Lidocaine 5% Patch for Treatment of Acute Pain After Robotic Cardiac Surgery and Prevention of Persistent Incisional Pain: A Randomized, Placebo-Controlled, Double-Blind Trial
    Vrooman, Bruce
    Kapural, Leonardo
    Sarwar, Sheryar
    Mascha, Edward J.
    Mihaljevic, Tomislav
    Gillinov, Marc
    Qavi, Shahbaz
    Sessler, Daniel I.
    PAIN MEDICINE, 2015, 16 (08) : 1610 - 1621
  • [24] Tramadol in Neuropathic Pain After Spinal Cord Injury A Randomized, Double-blind, Placebo-controlled Trial
    Norrbrink, Cecilia
    Lundeberg, Thomas
    CLINICAL JOURNAL OF PAIN, 2009, 25 (03): : 177 - 184
  • [25] Intravenous lidocaine in central pain -: A double-blind, placebo-controlled, psychophysical study
    Attal, N
    Gaudé, V
    Brasseur, L
    Dupuy, M
    Guirimand, F
    Parker, F
    Bouhassira, D
    NEUROLOGY, 2000, 54 (03) : 564 - 574
  • [26] Intravenous Lidocaine for Effective Pain Relief after Inguinal Herniorrhaphy: a Prospective, Randomized, Double-blind, Placebo-controlled Study
    Kang, H.
    Kim, B-G
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (02) : 435 - 445
  • [27] Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: A randomized double-blind controlled trial
    Jia, Zhen
    Chen, Yi
    Gao, Tianyu
    Yuan, Yuan
    Zheng, Yuxin
    Xie, Yegong
    Wang, Guolin
    Yu, Yonghao
    Zhang, Linlin
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [28] Intravenous Lidocaine for Effective Pain Relief After a Laparoscopic Colectomy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study
    Ahn, EunJin
    Kang, Hyun
    Choi, Geun Joo
    Park, Yong Hee
    Yang, So Young
    Kim, Beom Gyu
    Choi, Seung Won
    INTERNATIONAL SURGERY, 2015, 100 (03) : 394 - 401
  • [29] Tramadol in the treatment of neuropathic cancer pain - A double-blind, placebo-controlled study
    Arbaiza, Daniel
    Vidal, Oscar
    CLINICAL DRUG INVESTIGATION, 2007, 27 (01) : 75 - 83
  • [30] Analgesic response after a bolus of intravenous lidocaine in the treatment of neuropathic pain: A randomized, double blind, placebo-controlled trial
    Tremont-Lukats, IW
    Backonja, MM
    NEUROLOGY, 2000, 54 (07) : A81 - A82